Table 1 Baseline characteristics (based on local assessment).
Characteristic | Part 1 (dose finding) | Part 2 (dose expansion) | |
|---|---|---|---|
Cohorts 1 and 2 (n = 9) | Ovarian cancer, Arms A + B (n = 14) | TNBC, Arm C (n = 5) | |
Median age, years (range) | 61 (48–77) | 60 (34–80) | 49 (30–57) |
Region, n (%) | |||
Europe | 6 (67) | 13 (93) | 5 (100) |
Australia | 3 (33) | 1 (7) | 0 |
Race, n (%) | |||
White | 9 (100) | 14 (100) | 1 (20) |
Black or African American | 0 | 0 | 1 (20) |
Unknown | 0 | 0 | 3 (60) |
Baseline ECOG PS, n (%) | |||
0 | 7 (78) | 11 (79) | 3 (60) |
1 | 2 (22) | 3 (21) | 2 (40) |
BRCA1 or BRCA2 mutation status, n (%) | |||
Deleterious variant detected | 2 (22) | 9 (64) | 4 (80) |
Deleterious variant not detected | 7 (78) | 1 (7) | 0 |
Missing | 0 | 4 (29) | 1 (20) |
LOH status, n (%) | |||
≥16% | 2 (22) | 9 (64) | 4 (80) |
<16% | 0 | 0 | 0 |
Missing/not done | 7 (78) | 5 (36) | 1 (20) |
PD-L1 status, n (%) | |||
IC < 1% (negative) | 5 (56) | 4 (29) | 1 (20) |
IC ≥ 1% (positive) | 4 (44) | 7 (50) | 0 |
Missing/not done | 0 | 3 (21) | 4 (80) |
